Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,501–1,600 of 2,053
Handley, D., Gillett, A. C., Bala, R., Tyrrell, J., & Lewis, C. M. (2024) · medRxiv · doi:10.1101/2024.09.18.24313910
Comprensión y manejo de la diabetes mellitus: una revisión bibliográfica
Guevara, J. R. Z., Pineda, R., Morales, J. P., & Loor, T. A. S. (2024) · Revista Científica Multidisciplinaria SAPIENTIAE · doi:10.56124/sapientiae.v7i15.008 · Cited by 3
An SMS-Guided Basal Insulin Titration in People with Type 2 Diabetes New on Insulin
Snel, T., Reinhardt, S., Koenig, H., Pleus, S., & Freckmann, G. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01650-2 · Cited by 2
“However, initiating insulin therapy is a complex process that necessitates comprehensive education, close monitoring, and ongoing support [7, 8].”
BackgroundDiabetes Management with Current Guidelines.
Karadeniz, Y. (2023) · doi:10.69860/nobel.9786053359111.12
Rahimi, S., Mikaeli, N., Narimani, M., et al. (2024) · Journal of Health and Hygiene · doi:10.61186/j.health.15.2.218
Alsararatee, H. H. (2024) · British Journal of Nursing · doi:10.12968/bjon.2024.0280
Harrington, J., Kang, Y. M., & McGuire, D. K. (2024) · Diabetes Care · doi:10.2337/dci24-0061
Curalin supplement as add-on therapy for type 2 diabetes Mellitus
Raz, I., Sibony, R. W., Dor, S., Rozenberg, A., Yanuv, I., Yigdal, O., Elul, R., & Segev, O. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111912
Design and Evaluation of a Novel Plga-Alginate Nanocomposite for Sustained Release of GlipizidePreprint
Philip, A. K., Samuel, B. A., Mohammad, B. I., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4998669
Matvejeva, D., Nováková, M., Piťhová, P., & Kvapil, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.085
Kang, M., Son, K., Hwang, Y., Lee, S., Sang, H., Kim, S. Y., Yon, D. K., Rhee, S. Y., & Lim, H. (2024) · Diabetes · doi:10.2337/db23-0798
Amadi, P. U., Osuoha, J. O., Ekweogu, C. N., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5007261
Prediabetes: Modern entity with numerous risk factors
Petković, M. M., & Živković, T. B. (2024) · Medicinski podmladak · doi:10.5937/mp75-45793
Bogaert, L., Dirinck, E. L., Calders, P., Helleputte, S., Lapauw, B., Marlier, J., Verbestel, V., & Craemer, M. D. (2024) · Diabetic Medicine · doi:10.1111/dme.15473
“45 However, none of the studies included in this review investigated explanatory variables of all three behaviours simultaneously, highlighting a notable knowledge gap that requires further investigation.”
Guerra, C., Corréard, F., Montégut, C., Nakache, J., Mascio, T. D., Villani, P., Honoré, S., Daumas, A., Couderc, A., & Bérard, C. (2024) · Research Square · doi:10.21203/rs.3.rs-5349587/v1
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0591
Dynamic Treatment Regimes (Updated)
Moodie, E. E. M., & Stephens, D. A. (2024) · Wiley eBooks · doi:10.1002/9781118445112.stat08040.pub2
Diabetische Retinopathie und diabetisches Makulaödem
Ziemssen, F., & Gelişken, F. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-65929-8_44-1
Jack, I. G., Caldwell, E., Murray, A., McPherson, P. A. C., McCarron, P. A., & Irwin, N. (2024) · Pharmacy Education · doi:10.46542/pe.2024.241.734744 · Cited by 1
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
Butt, N. I., Ghoauri, M. S. A., Dur-e-Sabeh, et al. (2024) · Sri Lanka Journal of Medicine · doi:10.4038/sljm.v33i3.549
Chen, L., Wan, H., Han, J., Yang, C., Shao, H., Li, J., Yan, W., Xiao, J., Sun, Y., Li, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16144
“1,23,24 Nota-bly, after switching to Gla-300, a statistically significant increase in insulin dose of 0.14 U/kg at week 24 was observed, which was consistent when stratified by previous BI treatment.”
InfluentialMerker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01273-y
Rita, R. S., Yetti, H., Santoso, P., & Afriani, N. (2024) · Medical Laboratory Technology Journal · doi:10.31964/mltj.v10i2.621 · Cited by 1
“Oxidative stress from hyperglycemia may result in harmful complications (Davies et al., 2022; Huang et al., 2017; Umpierrez & Pasquel, 2017).”
大塚, 英., 小林, 俊., & 岡島, 史. (2024) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.20.276
Launbo, N., Pedersen, H., van Elst, C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5060308
Evaluating the Impact of Integrating Ayurveda with Allopathy in Diabetes Management: A Meta-Analysis
Murugaiyan, V., Samuel, K. S. K. J., Kalaiselvan, S., & Marokey, A. S. (2024) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3310
Clinical Perspectives for Diagnosis and Treatment of Diabetic CardiomyopathyPreprint
Chen, D., Sindone, A. P., Huang, M. L. H., Peter, K., & Jenkins, A. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5072684
Kaundu, S., Mwitwa, K., Siame, L. M., Luambia, I. N., Siabwacha, A., & Yusuf, U. A. (2024) · Journal of Phytomolecules and Pharmacology · doi:10.56717/jpp.2024.v03i02.028 · Cited by 1
Parikh, K., Thosani, S., Joshi, A., Hajirnis, A., & Seth, C. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_971_24
“[9] Mumbai, as the economic capital of India, boasts a densely populated environment with residents from diverse socio‑economic backgrounds engaged in various fields of employment to meet their needs.”
(2000) · Time to knit · doi:10.1016/s1155-1941(23)46691-7
Anaya-Ambriz, E. J., Álvarez-Zavala, M., González-Hernández, L. A., Andrade-Villanueva, J. F., Zúñiga-Quiñones, S., Valle-Rodríguez, A., Holguín-Aguirre, T. E., & Sánchez-Reyes, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030914 · Cited by 1
“Therefore, it has been suggested that PLWT2D should maintain adequate glycemic control and manage their lipid profile, which can be improved through lifestyle changes and pharmacological treatment with proper adherence [47].”
SGLT-2 inhibitors and diabetic ketoacidosis
Agozzino, F., Falco, T. D., & Villa, A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03862-1
Ghani, N. A., Hassan, S. N. F. S., Abidin, R. Z., Zakaria, Z., Nasir, F., & Azmi, A. Z. (2025) · Journal of Pharmacy · doi:10.31436/jop.v5i1.331
Mediterranean Diet and Biomarkers in At-Risk Groups
García-Gavilán, J. F., & Paz‐Graniel, I. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_83-1
Saboo, B., Khandelwal, D., Desai, P., et al. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0842
Kular, K. S., Gill, S. S., Manchanda, N., Rutledge, R., & Kular, K. S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07754-3
“While intensive medical therapy typically achieves HbA1c reductions of 1–1.5% [5] and lifestyle modifications show variable results (0.5–2% reductions), our technique achieved a sustained 6.46% reduction.”
InfluentialHan, Y., Zhang, J., Wang, W., Zhou, K., Yang, W., Pan, Q., Nie, Z., & Guo, L. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112073
Yagi, K., Chujo, D., Usui, I., Liu, J., Nohara, A., Enkaku, A., Takikawa, A., Honoki, H., Fujisaka, S., Origasa, H., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.103551 · Cited by 1
Sanyal, D., & Mitra, A. (2025) · Cureus · doi:10.7759/cureus.80050
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) emphasize individualized care [11].”
Sriphrapradang, C., Thakkinstian, A., Chinthammit, R., & Nayak, G. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14409 · Cited by 1
Primary Care and Diabetes Technologies and Treatments
Simonson, G. D., Martens, T. W., Carlson, A. L., & Bergenstal, R. M. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8810.gds
“Empowering individuals with diabetes self-management education and support (DSMES) is essential and is recommended and should be considered to be as important as pharmacotherapy (3).”
MicroRNA expression profiling in type 2 diabetes patients treated with liraglutide
Irshad, M., Yadav, S., Mathkor, D. M., Babegi, A. S., & Haque, S. (2025) · Journal of King Saud University - Science · doi:10.25259/jksus_103_2024
Helbert, S., & Hardy, A.-F. (2025) · Recherche en soins infirmiers · doi:10.3917/rsi.159.0012
Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetes aktuell · doi:10.1055/a-2539-0910
3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112147 · Cited by 1
MULAKWA, L. M., Charles, B. A., Serge, C. M., et al. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i3.1620
A PREDICTION MODEL FOR CHRONIC HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Koteliukh, M. Y., Бокова, С. І., Demikhova, N. V., & Lantukhova, N. D. (2025) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.2.2025.13 · Cited by 3
“Joint recommendations of the American Diabetes Association and the European Association for the Study of DM were used to diagnose and manage T2DM [9].”
Mcgill Empowerment Assessment-Diabetes Questionnaire: Turkish Validity and Reliability Study
Başak, S., Turan, G. B., & Özer, Z. (2025) · Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi · doi:10.46413/boneyusbad.1517554
Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!
Lee-Barkey, Y. H., Arbi, A., Parizova, S., Danch, E., Willecke, F., Stratmann, B., & Tan, S. (2025) · Gefässchirurgie · doi:10.1007/s00772-025-01211-2
Lange, K., & Landgraf, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01308-y
Herbal Medicine and Chronic Disease Management
Khare, P., & Khare, N. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815322910125010005 · Cited by 2
The Emerging Trend of Managing Type 2 Diabetes with Oral Semaglutide
Bhattacharyya, S. (2025) · Clinical Diabetology · doi:10.5603/cd.105996
Merker, L., Ebert, T., Schleicher, E. D., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2500-1124
“If this is not possible, glucagon-like peptide-1 (GLP-1) receptor agonists with proven cardiovascular benefit should be used[10, 11].”
Son, Y.-I., & Lee, S.-K. (2025) · Journal of Nutrition and Health · doi:10.4163/jnh.2025.58.2.179
Mohan, V., Sethi, B. K., Jain, S. M., Sahay, R. K., Balamurugan, R., Murthy, S., Singh, K. P., MENON, S. K., Gadekar, A. V., Salvi, V., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01736-5 · Cited by 1
“…the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), recommends initiation of basal insulin (BI) after lifestyle modifications and the failure of oral anti-hyperglycemic drugs (OADs) to achieve targeted glycosylated hemoglobin (HbA1c) levels [6, 7].”
Diabetische Retinopathie und diabetisches Makulaödem
Ziemssen, F., & Gelişken, F. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65823-9_44
Entzündungskrankheiten: Was leistet eine antientzündliche Ernährung?
Geisler, C., Dörge, M., & Laudes, M. (2025) · Diabetes aktuell · doi:10.1055/a-2563-8623
Antakly, Y., Moeuf, Y., Garçon, P., Kalaydjian, A., Banu, I., Voican, A., Dupuy, O., Cador, R., & Komajda, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16457
Sørensen, M., Kristensen, F., Nielsen, J. S., Christensen, D. H., Nicolaisen, S. K., Beck‐Nielsen, H., Vestergaard, P., Jessen, N., Olsen, M. H., Hansen, T. F., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112231
Okamoto, A., Yokokawa, H., Morimoto, A., Goto, K., Fukuda, H., Hisaoka, T., & Naito, T. (2025) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2025.152007
Zhang, H., Li, W., Wang, J., Wu, Z., Zhao, N., & Jiang, Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05063-5 · Cited by 1
“It is widely used not only for monitoring blood sugar levels in those diagnosed with diabetes but also for diagnosing the condition and identifying individuals at risk of developing it [12].”
Ponomareva, O. V., Смирнова, Е. А., & Shukis, K. A. (2025) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2025-15-3-233-240 · Cited by 1
Impact of metabolic health and weight transition on COVID-19 risk: A population-based cohort study
Park, Y., Kim, S. H., Ha, A., Kim, Y. K., Yoon, H., Kang, J., Kim, S.-E., Kim, Y. J., & Bae, Y. S. (2025) · Public Health · doi:10.1016/j.puhe.2025.105777
Braga, S. D. Q., Oliveira, M. C. A. M., Chamorro, M. J., de Jesus, N. A., Oliveira, R. A. M., da Silva, D. A. R., Rios, D. L. S., & das Mercês, M. C. (2025) · Healthcare · doi:10.3390/healthcare13111336
“From the third month, a shift in prescription patterns was observed, with a notable increase in the use of GLP-1 receptor agonists, whose efficacy for glycemic control and weight loss is well documented [23,24].”
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., & Soegondo, S. (2025) · F1000Research · doi:10.12688/f1000research.163923.1
Ohyama, K., Takahashi, T., AKIYAMA, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6728366/v1
ADHERENCE TO ORAL ANTIDIABETIC DRUGS IN PEOPLE WITH TYPE 2 DIABETES
Holdt‐Caspersen, N. S. (2025) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau784097848
Filimonovic, J. S. (2025) · Praxis medica · doi:10.70949/pramed202504000f
Deshmukh, V. C., Phadke, S. S., Agarwal, S., Kalra, S., Sahay, R. K., Viswanathan, V., Chawla, R., Bajaj, S., Phadke, L., Deshmukh, P., et al. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01506-w
Bridging the Gap in Diabetes Care Through Personalization: A Comprehensive Design Intervention
Chaudary, S., Ranade, P., & Verma, I. K. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-2179-8_14
Rare coexistence of pericardial tear and pneumopericardium in diabetic ketoacidosis: a case report
Jianping, Z., Zhang, W., & Wang, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112342
Дунаєва, І. (2025) · Medicine Today and Tomorrow · doi:10.35339/msz.2025.94.2.dun
Tahir, W., Beba, H., Fortes-Mayer, G., Kar, P. S., Khan, N., Milne, N., Moore, J., Saha, S., & Atkin, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-093955
Дунаєва, І. (2025) · Experimental and Clinical Medicine · doi:10.35339/ekm.2025.94.2.dun · Cited by 1
The Role of the Pharmacist in Clinical Scenarios
Presnell, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_16
Emerging role of GLP-1RAs in the management of diabetic kidney disease
Bellary, S. (2025) · British Journal of Diabetes · doi:10.15277/bjd.2025.478
Majd, Z., Cheruvu, S. S., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., & Abughosh, S. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2682989
Diabetes type 2 risk assessment in persons undergoing preventative examinations
Vujić-Jović, N., Hodžić, D., Jović, L., et al. (2025) · Glasnik javnog zdravlja · doi:10.5937/serbjph2502084v
Дунаєва, І. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.4.2025.1565
Luo, Z., Zhang, Z., Zheng, Y., Gao, Q., Wang, Y., & Liu, Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5339508
Holland, D., Halsall, I., Heald, A. H., Stedman, M., Hanna, F., & Fryer, A. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01766-z
“Its appropriate use is critical to ensuring the best clinical outcome and minimising complications [1, 2].”
Bengoa-Urrengoechea, I., Aguilar‐Palacio, I., Rabanaque, M. J., Lallana, M. J., Cabezas, A. G., & Malo, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530139
Chaudhuri, S., Biswas, S., Mukhopadhyay, S., & Dasgupta, S. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_492_24
“[5] Therefore, a comprehensive evaluation becomes possible for both the positive and side effects of the new drug with possible reduction of the potential risks and expenses.”
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Hepatogenous diabetes in liver cirrhosis
Roman, J. K. H., Attanasi, M. L., & Satapathy, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00017-5
Mimura, H., Oura, T., Chin, R., Hirase, T., & Shimono, D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01775-y · Cited by 1
“Additionally, T2D is recognized as a heterogeneous disease, with variable clinical characteristics and risks of comorbidities, requiring an individualized and personalized approach for optimal disease management [4].”
Yabe, D., Hamamoto, Y., Kawanami, D., Nishimura, R., Terauchi, Y., Amadid, H., Braae, U. C., Major‐Pedersen, A., & Suzuki, R. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70099 · Cited by 2
Carson, E., Khaleq, F., McDonald, C., Smith, N., & Colon, A. R. (2025) · Cureus · doi:10.7759/cureus.88898 · Cited by 1
“Despite this limited evidence, clinical guidelines do still recommend these agents, and they are being used in this population [13].”
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01344-8
Ho, M. K. H., Santhireswaran, A., Gomes, T., Mamdani, M., & Tadrous, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329299
Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience
Siderova, M. V., Shopov, G., Kehayova, G. K., & Dragomanova, S. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e163319
Ramadhani, I. N., & Sakti, H. S. (2025) · JURNAL BIOLOGI TROPIS · doi:10.29303/jbt.v25i3.9201
Lehmann, R., & Marx, N. (2025) · Cardiovascular System · doi:10.1007/978-3-662-70152-2_6
Papazachariou, A., Malikides, O., Malikides, V., Vasilaki, N., Stamatelatou, M., Papakitsou, I., Papadokostaki, E., & Filippatos, T. D. (2025) · Discover Public Health · doi:10.1186/s12982-025-00457-1 · Cited by 1
Bawa, T., & WANGNOO, S. K. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_5_25 · Cited by 1
Taking a Closer Look at Gliclazide – Benefits Beyond Glycemic Control
Bishnoi, A., Sur, A., GONSALVES, B. L., Atri, B., Goswami, S., Ravindranath, V., Patel, V., Prajapati, H. K., & Shah, D. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_25 · Cited by 2
Campos, C., King, A., Miller, E. M., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0040 · Cited by 1
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.